ATE401321T1 - Beta-lactame zur behandlung von erkrankungen des zns - Google Patents

Beta-lactame zur behandlung von erkrankungen des zns

Info

Publication number
ATE401321T1
ATE401321T1 AT04797809T AT04797809T ATE401321T1 AT E401321 T1 ATE401321 T1 AT E401321T1 AT 04797809 T AT04797809 T AT 04797809T AT 04797809 T AT04797809 T AT 04797809T AT E401321 T1 ATE401321 T1 AT E401321T1
Authority
AT
Austria
Prior art keywords
lactames
beta
treatment
cns diseases
cns
Prior art date
Application number
AT04797809T
Other languages
English (en)
Inventor
Giuseppe Alvaro
Fabio Romano Di
Riccardo Giovannini
Alfredo Paio
Maria Elvira Tranquillini
Lucia Mattioli
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE401321T1 publication Critical patent/ATE401321T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04797809T 2003-11-12 2004-11-10 Beta-lactame zur behandlung von erkrankungen des zns ATE401321T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0326407.4A GB0326407D0 (en) 2003-11-12 2003-11-12 Chemical compounds

Publications (1)

Publication Number Publication Date
ATE401321T1 true ATE401321T1 (de) 2008-08-15

Family

ID=29726427

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04797809T ATE401321T1 (de) 2003-11-12 2004-11-10 Beta-lactame zur behandlung von erkrankungen des zns

Country Status (28)

Country Link
US (1) US20080262041A1 (de)
EP (1) EP1689737B1 (de)
JP (1) JP2007510692A (de)
KR (1) KR20060118477A (de)
CN (1) CN1878764A (de)
AR (1) AR046233A1 (de)
AT (1) ATE401321T1 (de)
AU (1) AU2004291296B2 (de)
BR (1) BRPI0416285A (de)
CA (1) CA2546007A1 (de)
CY (1) CY1108404T1 (de)
DE (1) DE602004015144D1 (de)
DK (1) DK1689737T3 (de)
ES (1) ES2310295T3 (de)
GB (1) GB0326407D0 (de)
HK (1) HK1094698A1 (de)
HR (1) HRP20080501T3 (de)
IL (1) IL175279A0 (de)
IS (1) IS8477A (de)
MA (1) MA28156A1 (de)
MY (1) MY138378A (de)
NO (1) NO20062661L (de)
PL (1) PL1689737T3 (de)
PT (1) PT1689737E (de)
RU (1) RU2006120417A (de)
SI (1) SI1689737T1 (de)
TW (1) TW200528439A (de)
WO (1) WO2005049600A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015200142B2 (en) * 2006-01-24 2016-07-07 Unilever Plc Novel lactams
US9586901B2 (en) 2006-01-24 2017-03-07 Unilever Plc Lactams

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262366A (de) * 1960-03-14
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2083891A1 (en) * 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB9200535D0 (en) * 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5824690A (en) * 1993-05-06 1998-10-20 Hoechst Marion Roussel Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
CN1067385C (zh) * 1994-08-25 2001-06-20 默里尔药物公司 用于治疗变应性疾病的新的取代的哌啶类化合物
US5780466A (en) * 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US6211199B1 (en) * 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
FR2779429B1 (fr) * 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
US6204265B1 (en) * 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
GB0114867D0 (en) * 2001-06-18 2001-08-08 Merck Sharp & Dohme Therapeutic agents
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HK1094698A1 (en) 2007-04-04
EP1689737A1 (de) 2006-08-16
CY1108404T1 (el) 2014-02-12
SI1689737T1 (sl) 2008-12-31
BRPI0416285A (pt) 2007-01-23
ES2310295T3 (es) 2009-01-01
DK1689737T3 (da) 2008-10-27
IS8477A (is) 2006-05-22
WO2005049600A1 (en) 2005-06-02
NO20062661L (no) 2006-06-09
CA2546007A1 (en) 2005-06-02
US20080262041A1 (en) 2008-10-23
RU2006120417A (ru) 2007-12-27
PL1689737T3 (pl) 2008-12-31
IL175279A0 (en) 2006-09-05
AU2004291296B2 (en) 2011-04-07
KR20060118477A (ko) 2006-11-23
GB0326407D0 (en) 2003-12-17
JP2007510692A (ja) 2007-04-26
HRP20080501T3 (en) 2008-11-30
MY138378A (en) 2009-05-29
AU2004291296A1 (en) 2005-06-02
DE602004015144D1 (de) 2008-08-28
MA28156A1 (fr) 2006-09-01
EP1689737B1 (de) 2008-07-16
CN1878764A (zh) 2006-12-13
PT1689737E (pt) 2008-10-24
TW200528439A (en) 2005-09-01
AR046233A1 (es) 2005-11-30

Similar Documents

Publication Publication Date Title
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE557022T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
ATE542801T1 (de) Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60328494D1 (de) Verbessertes system zur behandlung der stressbedingten harninkontinenz
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689737

Country of ref document: EP